Braveheart Bio, Inc. (BRVE) Insider Trading

Braveheart Bio, Inc. (BRVE) has 14 SEC Form 4 insider filings on record in the last 90 days. That includes 10 insider purchases totalling $159.0M. Most recent filing: Aug. 11, 2026.

Filings
14
Purchases
10
$159.0M
Sales
0
$0
Insiders
13

Most active BRVE insiders

Forbion Growth Opportunities Fund III Cooperatief U.A.
10% Owner
1 bought · 0 sold · Aug. 7, 2026
$64.8M
ORBIMED ADVISORS LLC
Director
1 bought · 0 sold · Aug. 11, 2026
$34.9M
Chimovits Erez
Director
1 bought · 0 sold · Aug. 11, 2026
$34.9M
AH Bio Fund IV, L.P.
10% Owner
1 bought · 0 sold · Aug. 11, 2026
$19.8M
Viehbacher Christopher
Director
1 bought · 0 sold · Aug. 7, 2026
$1.5M
Murdoch Travis
CEO and President
1 bought · 0 sold · Aug. 7, 2026
$1.5M
Lubner David Charles
Director
1 bought · 0 sold · Aug. 7, 2026
$1000K
Rickey James Paul
Chief Financial Officer
1 bought · 0 sold · Aug. 7, 2026
$500K

Latest BRVE Form 4 filings

Date Insider Value Shares Stake Pre-planned Links
Aug. 11, 2026 filed Aug. 7, 2026 AH Bio Fund IV, L.P. 10% Owner +$19,800,000 50,232,420 No
Aug. 11, 2026 filed Aug. 7, 2026 Chimovits Erez Director +$34,920,000 51,072,420 No
Aug. 11, 2026 filed Aug. 7, 2026 ORBIMED ADVISORS LLC Director +$34,920,000 51,072,420 No
Aug. 10, 2026 filed Aug. 7, 2026 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% Owner $0 39,920,091 No
Aug. 7, 2026 Forbion Growth Opportunities Fund III Cooperatief U.A. 10% Owner +$64,800,000 95,723,287 No

Showing the 5 most recent of 14 filings in the last 90 days.

About this data

Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.

Get alerted when BRVE insiders trade

Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.

Start free